Non-Hodgkin’s Lymphoma | Pharmacor | G7 | 2015

Last Updated 2 November 2015
Fueled by multiple label expansions of premium-priced agents and the launch of four novel therapies, the NHL market will experience significant growth over the ten-year forecast period. This comes despite biosimilar erosion expected for rituximab, the patient share and sales leader in 2014, and generic erosion for bendamustine, the second best-selling agent across the NHL market in 2014. Untapped clinical and commercial potential remains in NHL for therapies with improved efficacy and for agents positioned in patient segments that are currently underserved.